G. Michael Wall, Ph.D. Email and Phone Number
G. Michael Wall, Ph.D. work email
- Valid
G. Michael Wall, Ph.D. personal email
Broad pharmaceutical industrial experience, leading all development activities for solid oral, injectable, topical, inhalation, sterile or non-sterile, drug products, drug/device and medical devices. Accomplished technical leader of international, culturally diverse, multidisciplinary, and virtual teams. Enjoys blend of science, medicine and business in interactions not only with scientific partners and regulatory bodies but also with marketing, medical affairs, sales and key opinion leaders in the development of new therapeutic agents, Phase I-IV. Experienced in seeking angel and venture capital funding as well as virtual company operation. Significantly experienced in pharmaceutical development under Australian Government’s generous R&D Tax Incentive program.Specialties: anticounterfeit; consultant; pharmaceutical; biotech; Australia; New Zealand; USA; EU; Iceland; combination drug product; formulation development; medical device; nitrosamines; oral; capsule, amorphous; resupendability; tablet; spray dried dispersion; injectable; sterile; intravitreal; implant; topical; nasal spray; otic; post-surgical ocular inflammation; blepharitis; ophthalmology; ophthalmic; insert; ocular; post-vitrectomy; cataract; presbyopia; pediatric; allergy; infection; inhalation; dermatology; dermatitis; radiation; otomycosis; nebulized; nebulization; peptide; oligonucleotide; biological; drug product; analytical; medicinal; preclinical; clinical trial material supplies; investigational medicinal product (IMP); phase 1 2 3 4; promotional; launch; medical affairs; regulatory affairs; antibiotic; amino acid; aminoglycoside; antioxidant; glutathione; fluoroquinolone; N-chloro-taurine; anti-inflammatory; selenium; chemotherapy; pneumonia; ear; lung; melanoma; oncology; Friedreich's Ataxia; myocardial myopathy; neurology; orphan; ball milling; Netzch; microfluidization; nanosuspension; polymorph; co-crystal; pulmonary fibrosis; age-related macular degeneration; anterior posterior segment; chronic kidney disease; Covid-19 (SARS-B CoV-2); cystic fibrosis; diabetic retinopathy macular edema diabetes; prostaglandin; fenofibrate, HCCAA, adrenergic; beta-blocker; retinitis pigmentosa; Usher; otolaryngology; neurotology; sensorineural; noise-induced; hearing loss; Meniere's disease; cystinosis; motor neuron disease; ALS ; ototoxicity; alliance; patents; intellectual property; program project management; licensing; diligence; quality; USP, CMC; IND; preIND; ISO; CTD; IMPD; EMA; FDA; NDA; MAA; BTD; Fast Track; HREC; IB; orphan; rare pediatric disease designation; voucher; RPV.
University Of Mississippi School Of Pharmacy
View-
Adjunct Professor Of Medicinal ChemistryUniversity Of Mississippi School Of PharmacyTexas, United States
-
Adjunct Professor Of Medicinal ChemistryUniversity Of Mississippi School Of Pharmacy Jan 2023 - PresentUniversity, Ms, Us
-
Therapeutic Matching Committee Leadership Group MemberUndiagnosed Diseases Network (Udn) Jul 2022 - PresentBoston, Ma, Us -
Usp Expert Committee Member 2020-2025Us Pharmacopeia Jun 2020 - PresentRockville, Maryland, Us -
Pharmaceutical ConsultantIntegration Pharma, Llc Feb 2019 - PresentAdvised virtual startup [confidential pharma company] in the development of NCE topical ocular antiinflammatory agent for the treatment of dry eye including formulation, container/closure, clinical trial design and Australian clinical trial. Advised virtual startup [confidential pharma company] in the development of sterile topical cream drug product for treatment of otic [unmet medical need]. Advised virtual startup [confidential pharma company] in the development of sterile topical cream drug product for treatment of chronic rhinosinusitis including formulation development, IP, preclinical, clinical, PreINDs, project management and prudent selection of Key Opinion Leaders as US consultants: Led FDA interactions. Led Australian development including preclinical (protocol design) and clinical (protocol design, IB, EC) efforts including prudent selection of Key Opinion Leaders as AU consultants.
-
Svp & CsoNacuity Pharmaceuticals, Inc. Dec 2016 - PresentFort Worth, Texas, UsLead CMC (GMP), nonclinical, clinical, regulatory developmental activities in US and Australia for antioxidant NCEs, oral, sterile topical ophthalmic eye drops, inserts and intravitreal implants, for the treatment of [unmet medical needs including orphan designation, rare pediatric disease designation] -
Vp, Pharmaceutical DevelopmentSound Pharmaceuticals, Inc. Oct 2016 - PresentSeattle, Wa, UsLead pharmaceutical development of organoselenium NCE for the treatment of patients under 5 INDs (including fast track) (US) and 1 CTA (UK) including Meniere’s disease, sensorineural hearing loss, chemotherapy-induced ototoxicity, aminoglycoside-induced ototoxicity, Covid-19 (SARS-CoV-2) and bipolar disorder. Capsules; tablets; clinical trial material (CTM); investigational medicinal product (IMP); preformulation; solid-state; polymorphism; drug/device implants. -
Pharmaceutical ConsultantEar, Nose And Throat Health, Llc Aug 2011 - PresentProvided consulting services to large and small pharmaceutical companies in the U.S., Europe, Middle East and Asia, for the development of branded or generic, sterile inhaled, injectable or topical, solutions, viscous solutions or suspensions (including nanosuspensions, involving ball-milling, Netzch milling, cryoprecipitation or microfluidization), as well as non-sterile oral (capsules, tablets), nasal and topical drug products, including formulation development, IP, preclinical, clinical, PreINDs, project management for virtual organizations, prudent selection of CROs and CMOs: -Led CMC development of solid oral dosage form for [confidential company] for [unmet medical need]; amorphous dispersions, hot melt extrusions, polymorphs, co-crystals -Effectively leveraged CROs/CMOs and led pharmaceutical development (PM, formulation, manufacturing, preclinical, clinical study designs) of new ophthalmic drug/device combination product [505(b)(2)] for treatment of [unmet medical need] for [virtual company confidential].-CMC development for NCE sterile inhaled biologicals (peptides, oligonucleotides) for treatment [unmet medical need] for [company confidential].-Led formulation development for otic NCE drug product for treatment of [unmet medical need] for [virtual company confidential].-Advised [virtual company confidential] regarding pharmaceutical development of otic NCE drug product for treatment of [unment medical need].-Drafted PreIND for [virtual company confidential] regarding development of otic NCE drug product for treatment of middle ear infection.-Advised [virtual company confidential] regarding pharmaceutical development of 505(b)(2) ENT drug product for treatment of [unmet medical need (infection)].-Advised [non-US company confidential] regarding formulation development of generic injectable drug product.-Advised attorneys regarding patent prosecution and successful defense in challenges to U.S. and European patents.
-
Senior Director, Chemistry, Manufacturing And Controls, Regulatory AffairsReata Pharmaceuticals, Inc. Apr 2012 - Dec 2014Plano, Texas, UsLed CMC projects, CMC-RA activities in a virtual company environment for development and manufacture of solid, oral dosage forms, as well as topical dosage forms, of novel class of anti-inflammatory immunomodulators, including bardoxolone methyl, omaveloxolone (RTA 408) and analogs; managed CMC activities with external partners, Abbvie and Kyowa Hakko Kirin; developed CMC sections for INDs, IMPDs; outsourced manufacturing, packaging, labeling, distribution of global clinical trial material through CMOs and CROs; authored regulatory CMC sections and outsourced through CRO/CMOs the investigational product manufacture, packaging, labeling and distribution for 8 US clinical trials. -
Vp, Product And Business DevelopmentO Ray Pharma, Inc. 2011 - 2012Otolaryngological product and business development; cochlear implant; medical device; nutritional supplements, bacterial sinusitis research; drug-eluting vaginal ring; generic drugs; over-the-counter drugs; pre-IND; NIH grant application
-
Vp, Product DevelopmentOtonomy, Inc. 2011 - 2011San Diego, Ca, UsLead all aspects of sterile injectable drug product development. Oversee and manage interactions with Key Opinion Leaders and Professional Societies. Maintain quality assurance for all IND-related activities. -
Senior Director, Pharmaceutical DevelopmentAlcon Laboratories, Inc. 2005 - 2010Geneva, Switzerland, ChLed all aspects of global development for ophthalmic, otic and nasal drug products; led preclinical, clinical development and approval (including pediatric exclusivity) of Patanase® Nasal Spray for the treatment of allergic rhinitis in children and adults (Patanase® is the #1 intranasal antihistamine prescribed by U.S. pediatricians); strategically planned and managed annual budgets over $30M; directed scientific aspects of meetings with Antiinfective Division of US FDA, European national agencies; outsourced research to numerous universities, research institutes and CROs; Stage Gate Model, Program Management with Project Office and Planisware Software; liaison between R&D and Marketing, Sales and Key Opinion Leaders; alliance management involvement; technically assessed license opportunities. Cumulative 2004-10 sales of otolaryngology products developed exceeded $2 billion. -
Medical Specialty DirectorAlcon Laboratories, Inc. 2000 - 2005Geneva, Switzerland, ChCreated two new successful therapeutic specialty areas, otic and nasal drug and device products; led preclinical, clinical development and approval for Ciprodex® Otic Suspension (two indications, AOE and AOMT in patients ages 6 months and older), now the #1 eardrop prescribed by ENTs and pediatricians in the U.S.; approved promotional materials; led Team to approval for Ciloxan® Ear Drops, Solution (infection) (International); led Team to approval of re-formulated Cipro®HC Otic Suspension (U.S., International); developed Sofenz® Cerumenolytic Solution, CE-marked medical device for Europe; directed meetings with Antiinfective, Pulmonary Divisions of FDA and EU agencies; outsourced research to universities, research institutes and CROs; led preclinical and/or clinical development programs for antiinfectives, antihistamines, corticosteroids, enzymes, viscoelastics and novel packaging
-
Assistant Director, International DevelopmentAlcon Laboratories, Inc. 1998 - 1999Geneva, Switzerland, ChDirected preclinical and clinical activities for ophthalmic, nasal & otic drug products; plan, budget, supervise and manage preclinical and clinical programs; represented sponsor in FDA/EMEA/CHMP meetings; responsible for international clinical/registration for AZOPT® (glaucoma), PATANOL® (ocular allergy), and TRAVATAN® (glaucoma).
-
Assistant Director, Global StabilityAlcon Laboratories, Inc. 1995 - 1998Geneva, Switzerland, ChSupervised chemists responsible for global stability programs, 75,000 tests/year; released domestic and international clinical and toxicology supplies, 6000 tests/year; managed ~4000-ft2 computer-monitored stability facility, ~2500 studies in 29 chambers; directed design and planning for new 11,000 ft2 stability storage facility; directed implementation of company's first computerized LIMS system; led multidisciplinary teams in development of otic and ophthalmic products
G. Michael Wall, Ph.D. Skills
G. Michael Wall, Ph.D. Education Details
-
Harvard Business School Executive EducationAdvanced Management Program #168 -
University Of MississippiSchool Of Pharmacy
-
Auburn University Harrison College Of PharmacyMedicinal Chemistry
-
Auburn UniversityChemistry
Frequently Asked Questions about G. Michael Wall, Ph.D.
What company does G. Michael Wall, Ph.D. work for?
G. Michael Wall, Ph.D. works for University Of Mississippi School Of Pharmacy
What is G. Michael Wall, Ph.D.'s role at the current company?
G. Michael Wall, Ph.D.'s current role is Adjunct Professor of Medicinal Chemistry.
What is G. Michael Wall, Ph.D.'s email address?
G. Michael Wall, Ph.D.'s email address is mi****@****abs.com
What schools did G. Michael Wall, Ph.D. attend?
G. Michael Wall, Ph.D. attended Harvard Business School Executive Education, University Of Mississippi, Auburn University Harrison College Of Pharmacy, Auburn University.
What skills is G. Michael Wall, Ph.D. known for?
G. Michael Wall, Ph.D. has skills like Drug Development, Pharmaceutical Industry, Clinical Development, Fda, Regulatory Affairs, Clinical Trials, Medical Devices, Clinical Research, Biotechnology, Ind, Ophthalmology, Cro.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial